1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Estonia Pharmaceuticals and Healthcare Report Q4 2015

Estonia Pharmaceuticals and Healthcare Report Q4 2015

  • September 2015
  • -
  • Business Monitor International
  • -
  • 101 pages

Includes 3 FREE quarterly updates

BMI View: We expect growth in Estonia's healthcare expenditure to decelerate over the long term given thecountry's fiscally conservative nature, the limited capacity of the national health insurer to accommodatefurther healthcare spending growth and BMI's outlook for the country's economy over the long term.Drugmakers can expect to see constrained revenue growth in the country as pricing pressures and restrictivedrug reimbursement will be employed by the Estonian health insurance fund to restrict healthcareexpenditure.

Headline Expenditure Projections

- Pharmaceuticals: Sales will rise from EUR292mn (USD391mn) in 2014 to EUR310mn (USD341mn) in2015, up 6.3% in local currency terms and down 12.8% in US dollar terms. Forecast revised upwardsfrom last quarter.

- Healthcare: Spending will rise from EUR1.15bn (USD1.54bn) in 2014 to EUR1.21bn (USD1.34bn) in2015, up 6.0% in local currency terms and down 13.0% in US dollar terms. Forecast revised upwardsfrom last quarter.

Table Of Contents

Estonia Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 14
Pharmaceutical Market Forecast 14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Estonia 2011-2019) 16
Healthcare Market Forecast 16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2011-2019) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2011-2019) 18
Prescription Drug Market Forecast 19
Table: Leading Anatomical Therapeutic Chemical (ATC) Groups By Pharmaceutical Sales, 2004-2010 (%) 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Estonia 2011-2019) 22
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Estonia 2011-2019) 24
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Estonia 2011-2019) 26
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Estonia 2011-2019) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Estonia 2013-2019) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Estonia 2013-2019) 31
Key Risks To BMI's Forecast Scenario 31
Macroeconomic Forecasts 32
Economic Analysis 32
Table: Economic Activity (Estonia 2010-2019) 36
Industry Risk/Reward Indices 37
Central And Eastern Europe Risk/Reward Index - Q4 2015 37
Estonia Risk/Reward Index 43
Rewards 43
Risks 43
Market Overview 45
Industry Trends And Developments 47
Epidemiology 47
Table: Leading Causes Of Death, 2005-2010 48
Healthcare Sector 49
Healthcare Reform 51
Healthcare Provision 51
Table: Healthcare Resources (Estonia 2009-2014) 52
Table: Healthcare Personnel (Estonia 2009-2014) 52
Table: Healthcare Activity (Estonia 2009-2014) 53
Healthcare Funding 53
Table: HIF Healthcare Expenditure, 2006-2011 (EURmn) 54
Healthcare Insurance 54
Table: Reimbursement Spending By Key Therapeutic Area, 2010-2011 (EURmn) 55
Table: Medicinal Products Reimbursed For Insured Patients, 2009-2011 (EURmn) 56
Healthcare Tourism 56
Research And Development 57
Table: Members Of EBio, 2011 57
Clinical Trials 59
Table: Number Of Clinical Trials, 1991-2011 60
Regulatory Development 61
Table: Key Health Insurance Indicators, 2007-2011 67
Table: Expenditure By Reimbursed Prescription Medicinal Products, 2005-2010 (EEK '000) 68
Competitive Landscape 70
Table: Members Of The Association Of International Pharmaceutical Manufacturers In Estonia 71
Generic Drugmakers 71
Pharmaceutical Distribution 72
Pharmaceutical Retail Sector 73
Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 73
Company Profile 76
GlaxoSmithKline 76
Grindeks (incorporating Tallinn Pharmaceutical Plant) 78
Merck and Co 82
Novartis 84
Pfizer 86
Sanofi 88
Demographic Forecast 90
Table: Population Headline Indicators (Estonia 1990-2025) 91
Table: Key Population Ratios (Estonia 1990-2025) 91
Table: Urban/Rural Population and Life Expectancy (Estonia 1990-2025) 92
Table: Population By Age Group (Estonia 1990-2025) 92
Table: Population By Age Group % (Estonia 1990-2025) 93
Glossary 95
Methodology 97
Pharmaceutical Expenditure Forecast Model 97
Healthcare Expenditure Forecast Model 97
Notes On Methodology 98
Risk/Reward Index Methodology 99
Index Overview 100
Table: Pharmaceutical Risk/Reward Index Indicators 100
Indicator Weightings 101

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.